Respiratory Flashcards

1
Q

Allergic bronchopulmonary aspergillosis

ABPA

A

incidence: 2-15% of all CLD (2-32% asthmatics, 7% CF)

cause: exaggerated response of the immune system to aspergillus

pathophysiology: hypersensitivity response causing damage to lung parenchyma with subsequent bronchiectasis/fibrosis

clinical:

  • acute/subacute deterioration in respiratory function
  • fever, malaise, brown mucous plugs, haemoptysis, eosinophilia
  • should be consider if deterioration does not respond to AB in 1 week

diagnosis: serum IgE>1000IU, positive skin test reactivity to aspergillus, positive IgE anti-aspergillus

CXR: tram line shadows due to ectatic bronchi, ring shadows, gloved finger shadows, branched tubular radiodecities extending from hilum

CT: proximal cylindrical bronchiectasis (UL>LL)

treatment: glucocorticoids 14 days and taper 3-6 months, itraconazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Alveolar Gas Equation

A

PAO2= PIO2- oxygen consumed

PAO2= PIO2 - (PaCO2/RQ)

where PIO2= (PATM-PH2O)xFIO2

* PATM at sea level is 760

* PH2O= 47

*FIO2 RA is 0.21

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Asthma

A

incidence: 15% children (1 in 6)

classification: 75% have infrequent episodic asthma

  • see table
  • intermittent infantile wheeze: no hx atopy
  • persistent wheeze: hx atopy, later decrease lung function

pathophysiology:

  • viral in 85% exacerbations

negative factors: ICU admission, poor compliance/control, interval sx, salbutamol use ++, exac by food

deaths: 33% mild, 33% no previous admission, 36% severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Asthma

-medications-

A

Relievers

short acting beta2 agonist: salbutamol, terbutaline

inhaled CS/long beta2 agonist: budesonide

anticholinergic bronchodilators: ipratropium

theophylline: aminophylline (methylxanthine: PDE inhib, adenosine antagonist)

Preventers

inhaled CS: beclomethasone, budesonide, fluticasone

inhaled CS/long beta2 agonist: budesonide, fluticasone

leukotriene receptor antagonist: montelukast

cromones (mast cell stabilisers): sodium cromoglycate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Asthma

-preventer treatment-

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Atelectasis

A

pathophysiology:

- more common in children (increased compliance/decreased collaterals)

  • RML/RLL most common to collapse together (common supply)

types:

  1. Obstructive (most common) eg. asthma, CF
  2. Reabsorptive eg. pneumonia, NMD, post anaethetics
  3. Relaxation eg. pleural effusion, pneumothorax
  4. Compressive eg. space occupying lesion

diagnosis:

- RUL: triangle opacity, elevated right hilum, tenting diaphragm

- RML: (common) little impact, 10% volume

- RLL: prominent horizontal fissue, wedge opacity

management: fix cause, physio, IPPV?, mucolytics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Bordetella pertussis

A

organism: gram negative encapsulated coccobacillus

incidence: 20-40% school children with prolonged cough

incubation: 7-10 days

clinically 3 phases:

  1. Catarrhal (1-2wks): mild cough and coryza
  2. Paroxysmal (2-6wks): coughing attacks with inspiratory whoop and post-tussis vomiting
  3. Convalescent (wks-mths): gradual resolution

complications: apnoeas, seizures (2%), death (< 6 months)

atypical (young/vaccinated):

  • infants: minimal catarrhal, feeding difficulties, cyanosis, apnoea, NO whoop
  • vaccinated/older: milder, less apnoea/cyanosis

diagnosis: cough >14 days with paroxysms or whoop or vomits

treatment indicated if early, cough< 14 days, admission, complications

  • clarithomycin (syrup), azithromycin (tablet)

contact treatment: aimed to decrease spread to <6 months

  • same AB as above with DTPa

unimmunised contacts: exclude from school for 14 days OR after 5 days AB

pregnancy prophylaxis: At weeks 27-35 or immediately postpartum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Breathing mechanics

A

Pleural pressure resting= -5cm H20

Alveolar pressure: inspiration=-1cmH20 expiration=1cmH2O

Transpulmonary pressure= pleural-alveolar pressure

Compliance= change in vol./change in pressure (VIP)

Airway resistance=(8xlengthxviscosity)/(3.14radius4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bronchiectasis

A

definition: radiological evidence of bronchial dilation with chronic productive cough

causes:

  • primary immune deficiencies: SCID, X-linked agammaglobulinaemia, CVID
  • genetic defect: ciliary dyskinesia, CF
  • other: aspiration syndrome, post infective, obstructive (FB, TB, tumour)

pathophysiology: neutrophilic inflammation cause dilated airways, mucous gland hyperplasia, loss of cilia, destruction of airway wall and tortuous bronchial vessels

clinical: chronic moist cough, dyspnoea, wheeze, clubbing

CXR: signet ring size (bronchi>vessel)

treatment: AB, physio, nutrition, exercise, mucolytics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bronchiolitis obliterans

A

definition: rare chronic lung disease of bronchioles/small airways due to injury

pathophysiology: tissue repair with large amounts of granulation causing airway obstruction and obliteration

etiology:

  • infection: adenovirus**, pertussis, mycoplasma, influenza, measles
  • drugs: penicillamine (Cu chelator)
  • AI: connective tissue disease, GVHD, lung transplant

clinical: cough, tachypnoea, cyanosis

diagnosis:

bronchography: obstruction of bronchioles

VQ: moth eaten appearance with matched defects

biopsy: confirms diagnosis

PFT: obstructive then restrictive

treatment: transplant

prognosis: some die within weeks, otherwise chronic disability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Carboxyhaemoglobin

A

pathophysiology: Hb contact CO forming stable compound preventing delivery of oxygen to body

  • CO binds same site as O2 but 200x more strongly
  • decreased ability to offload other Hb bound oxygen
  • 15% bound myoglobin/cytochromes/NADPH impairing oxidation in mitochondria and can cause myocardial stunning
  • also inactives cytochrome oxidase impairing peripheral oxygen use
  • half life 4-6hours

source: combustion of carbon fuels

clinical: normal 3%

carbon monoxide poisoning

  • lethargy, dizziness, LOC

treatment: oxygen, hyperbaric chamber

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

CPAM

(Congenital Pulmonary Airway Malformation)

A

incidence: 2/100,000 births

pathogenesis: imbalance cell proliferation/apoptosis in organogenesis

pathology:

  • unilateral single lobe: usually lower lobe
  • hamartomatous lesions of cystic and adenomatous elements arising from the tracheal, bronchial, bronchiolar or alveolar tissue
  • can compromise growth of adjacent normal tissue
  • blood supply from pulmonary circulation

type 1 (60-70%): thin-walled cysts 2-10cm in diameters

type 2 (15-20%): multiple 0.5-2cm cysts and solid areas that blend into adjacent tissue

type 3 (5-10%): very large and involve entire lobe

clinical:

  • 2/3 diagnosed prenatally: can develop hydrops
  • 1/4 symptomatic at birth: respiratory distress

diagnosis: CXR then CT at 6 weeks even if CXR normal

treatment: surgical

survival: >95%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Chlamydia pneumonia

A

clinical: mild disease common with wheeze/hyperactive airways

  • extrapulmonary: meningoencephalitis, guillan-barre, reactive arthritis, mycocarditis

diagnosis: sputum

treatment: erythromycin <8yrs, doxycycline >8yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Chlamydia psittaci

-psittacosis-

A

transmission: birds

clinical: fever, headache, myalgia, dry cough, pulmonary sx

complications: respiratory failure, hepatitis, endocarditis, encephalitis

diagnosis:

  • CXR: lobar changes
  • CT: nodular changes with ground glass opaciites
  • serum: Ab testing

treatment: doxycycline/tetracycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Choanal atresia

A

incidence: 1/7000 girls>boys

definition: obliteration/blockage posterior nasal aperture

clinical:

  • unilateral (2/3): unilateral nasal discharge/obstruction
  • bilateral: upper airway obstruction, noisy breathing, cyanosis worse in feeding

diagnosis: catheter through nose then CT

associations: Treacher-Collins, CHARGE, heart/GU defects, VATER, Pfeiffer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chronic suppurative lung disease

A

definition: chronic endobronchial suppuration with or without bronchial dilation

clinical: productive cough worse on waking, haemoptysis, FTT, RTI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Eosinophilic granulomatosis

(Churg Strauss)

A

pathophysiology: necrotising vasculitis small/medium arteries

onset: 20-30s with pulmonary opacities

clinical:

  • chronic rhinosinusitis, asthma and peripheral blood eosinophilia
  • asthma cardinal feature (90%)
  • lung and skin (tender subcutaneous nodules) most commonly affected organs
  • prodromal phase, eosinophilic phase then vasculitis phase

diagnosis: clinical with eosinophilia >5000, ANCA +ve (60%)

treatment: systemic GC, cyclosphosphamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Community acquired pneumonia

  • pathogens-
A

Neonates:

<1 month: GBS, E.coli, Listeria, CMV, HSV

1-3 months: viral, S.pneumoniae, afebrile pneumonitis, S.aureus

Children:

3months-5 years: viral, S.pneumoniae, S.aureus

>5years: viral, Mycoplasma, S.pneumoniae, Chlamydia pneumoniae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Community acquired pneumonia

-lobar versus bronchopneumonia-

A

lobar: large portion of entire lobar

  • usually strep pneumonia or klebsiella in young healthy people
  • pathology: congestion, hepatisation and resolution

bronchopneumonia: centred on bronchi and surrounding alveoli

  • wider variety or organisms: staph, strep, H.influenza, P.aeruginosa
  • in individuals with commorbidities
  • pathology: diffuse areas of acute exudate may resolve with fibrous scarring
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Cough

A

definition:

acute: < 3 weeks

chronic:> 4 weeks

classification:

non-specific: no abnormal findings on CXR/PFTs

post viral: pre-school, paroxysmal cough night>day, trigger URTI, lasts 2-4 wks, NO wheeze/SOB

protracted bronchitis: prolonged wet cough <5yrs, trigger URTI, well child

psychogenic: adolescent F>M, throat clearing, ABSENT night, URTI

treatment: reassurance, reevaluation, trial bronchodilators if wheeze

  • NO antitussives: assoc deaths
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cystic Fibrosis

  • genetics-
A

incidence: 1/2,500

genetics: single gene chromosome 7 encoding CFTR (CF transmembrane conductance regulator)

  • ABC (ATP binding cassette) family of proteins
  • regulated chloride channel: phosphorylation R domain and presence of ATP

mutations: over 1300 identified

  • delta F508: 70% mutations in caucasians

5 classes of mutations (1-3 more severe)

Class I: defective protein production

  • premature termination mRNA with absent CFTR

Class II (included delta F508): defective protein processing

  • abnormal post-translation processing so not transported to right location

Class III: defective regulation

  • altered ATP response with decreased Cl channel activity
  • response to CFTR modulators (ivacaftor)

Class IV: defective conduction

  • reduced rate of ion flow and duration of opening

Class V: reduced amounts of CFTR

  • altered stability CFTR protein or mRNA

gene modifiers: account for difference in phenotype with genotypes

  • eg. TGF-beta 1, MBL

incomplete phenotype: 10% mild phenotype or limited to one organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Cystic fibrosis

-clinical-

A

pulmonary:

  • features: clubbing, barrel chest, anorexia, malaise
  • airway hypersensitivity: 50% wheeze, 50% respond SABA
  • complications: pneumothorax, haemoptysis
  • CXR: hyperinflation, prominent vascular markings UL>LL, bronchiectasis, cysts, peribronchial cuffing, tram tracking

sinus: panopacification of sinuses

pancreatic:

  • incidence: 2/3 pancreatic insufficiency
  • clinical: FTT, stetorrhoea, fat soluble vitamin deficiency
  • treatment: enzyme replacements, ADEK
  • complications: pancreatitis 10%, CF DM (20% by 20yrs)

GIT:

  • meconium ileus: 90% babies
  • distal ileal obstruction: 15% adults
  • rectal prolapse rare
  • GOR: transient relaxation LOS, increased abdominal pressure

reproduction:

  • males: >95% infertile due to sperm transport failure (absent vas deferens)
  • females: less fertile due to malaborption/thick cervical mucous

bones: decreased mineral density

renal: nephrolithiasis/nephocalcinosis due to enteric hyperoxaluria/hypercitraturia

DVT: often in presence CVC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Cystic fibrosis

-diagnosis-

A

Newborn screen (3 steps): 1. IRT, 2. Gene testing, 3. Sweat Cl

NBST: tests for immunoreactive trypsinogent (IRT)

  • 80% sensitivity

Sweat chloride test: abnormal >60mmol/L

Screening asymptomatic individuals:

  • partners known carriers
  • family hx CF
  • Ashkenazi Jews
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cystic fibrosis

-lung transplant-

A

indications:

  • FEV1<30% or rapidly declining
  • increasing exacerbations
  • recurrent/refractory pneumothoraces
  • recurrent haemoptysis not managed embolisation

contraindications: B.cepacia, respiratory failure/intubation, symptomatic, osteoporosis

prognosis: better outcome than other indications

  • 5yr survival 65%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Cystic fibrosis

-organisms-

A

S.aureus 64% (most common)

  • MSSA 52%, MRSA 19% (assoc decline FEV1)
  • airway inflammation additive effect with P.aeruginosa

Pseudomonas

  • hypoventilation/hypoxia which promotes biofilm and defect CFTR allow binding
  • assoc decline FEV1/survival
  • conversion of P.aeruginosa to mucoid phenotype worse prognosis

Burkholderia cepacia 3%

  • accelarated decline PFT/survival
  • highly resistant to multiple AB
  • lung transplant in infected assoc recurrent infection (CI)
  • treatment: bactrim, doxycycline, ceftazidime, meropenem

Haemophilus influenzae 20-30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Cystic fibrosis

-pathophysiology-

A

pathophysiology:

pulmonary

defect: inability to secrete NaCl/water causes thick secretions and chronic infections and defects in FA metabolism increase arachidonic acid causing inflammation

colonisation: S.aureus, P.aeruginosa, Burkholderia cepacia, H.influenzae, Stenotrophomonas maltophilia, Achromobacter, Non TB mycoplasma, Aspergillus

progression: chronic infection/neutrophils produce elastase and cause tissue destruction with air trapping/bronchiolitis/bronchitis/bronchiectasis

GIT

  • impaired bile/pancreatic secretions with maldigestion/malabsorption
  • CF related DM
  • intestinal obstruction/intussusception/rectal prolapse

skin

  • decreased NaCl absorption from skin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Exercise induced dyspnoea

A

incidence: usually adolescence

pathophysiology: 45% no bronchoconstriction and fall in lung function post exercise completion

causes:

  • exercise induced larygeal dysfunction: F>M, athletes, exertion/stress
  • vocal cord dysfunction
  • structural abnormality
  • ILD
28
Q

Flow-volume curve

A

obstructive: scooping of descending limb of curve on expiration only

restrictive: narrow based curve on inspiration/expiration

variable intrathoracic obstruction: expiratory defect

  • reduced FEF50%/FIF50%
  • eg. tracheomalacia, bronchogenic cysts, tumour

variable extrathoracic obstruction: inspiratory defect

  • elevated FEF50%/FIF50%
  • eg. laryngomalacia, tracheomalacia, vocal cord defect

fixed upper airway obstruction: reduced insp/exp flow

  • FEF50%/FIF50%=1
  • eg. tracheal stenosis, goitre
29
Q

Infantile afebrile pneumonia

A

pathology: chlamydia trachomatis**, CMV, mycoplasma, ureaplasma urealyticum

transmission: via genital tract

  • 30% of women carry C.trachomatic and >50% vertical transmission

clinical: onset 2 weeks- 4 months

  • inclusion conjunctivitis +/- pneumonia (no wheeze)

diagnosis:

  • serum: high eosinophils/IgG/IgM
  • CXR: hyperinflation with interstitial pulmonary infilatrates

treatment: erythromycin

30
Q

Interstitial Lung Diseases

A

incidence: rare in children

etiology

idiopathic:

  • acute interstitial pneumonia/diffuse alveolar damage: acute/severe deterioration with high mortality
  • non-specific interstitial pneumonia: expansion of alveolar by dense infiltrates
  • organising pneumonia: patchy areas or inflammation/pneumonia
  • lymphocytic interstitial pneumonia

ILD syndromes in infants

  • neuroendocrine cell hyperplasia of infancy: hyperinflation with air trapping
  • follicular bronchitis/bronchiolitis: airway inflammation
  • pulmonary interstitial glycogenosis
  • genetic abnormalities of surfactant production

clinical: tachypnoea, creps, hypoxia, diffuse infiltrates, clubbing, wheeze (20%)

PFTS: restrictive patterns

31
Q

Laryngeal malformations

A

cysts: asymptomatic but can cause intermittent obstruction due to filling with air

atresia/stenosis:

  • type 1: supraglottic obstruction, absent vestule, subglottic stenosis
  • type 2: supraglottic obstruction
  • type 3: perforated membranes partially obstructs glottis (web) presenting with asphyxia

clefts: failed fusion of posterior cartilage 6-7weeks

  • 1:10,000 M>F onset 5 months and diagnosis 3 years
  • types 1-4
  • presents with increased secretions, feeding issues, FTT< wheeze/stridor/aspiration, RTI
  • assoc GORD, tracheomalacia, DD

subglottic haemangiomas:

  • grow 12-18mths then stabilise + resolution of 50% by 5yr
  • beard distribution of facial haemangiomas assoc PHACE
  • treat propranolol

laryngeal papillomatosis

  • multiple polypoid growths of VC by HPV 2-3yrs
  • obtained via birth canal
  • hoarse, breathy, resp distress, obstruction
  • surgery/tracheo but not treatable
32
Q

Laryngomalacia

A

incidence: most common cause laryngomalacia 50-75%

sex: M>F 3:1

assoc other pathology 30%: tracheomalacia, subglottic stenosis, VC palsy

pathophysiology: surrounding structural malformation

  • 50% large floppy arytenoids, 25% floppy epiglottis, 25% short aryepiglottic folds
  • prolapse over larynx during inspiration

clinical: stridor 2weeks- 18months, abnormal voice, resp distress, poor feeding, FTT

  • causes GORD due to increased intrathoracic pressure to overcome obstruction

investigation: fluoroscopy, laryngoscopy/bronchoscopy

management:

  • 99% conservation
  • surgery if severe
33
Q

Length of action respiratory drugs

A

Salbutamol: 8 hours

Salmeterol: 48 hours

Ipratropium: 24 hours

Theophylline: 12-48 hours

Montelukast: 24 hours

Antihistamine: 72 hours

Nedocromil: 48 hours

Glucocorticoid: 2-3 weeks

34
Q

Lung abscess

A

pathophysiology: necrosis of pulmonary parenchyma by infection

causes: aspiration pneumonia, post tricuspid valve endocarditis (S.aureus), Lemierre’s syndrome, pharyngitis

organisms:

  • usually anaerobes from mouth: peptostreptococcus, prevotella, bacteroides, fusobacterium
  • others: S.aureus, K.pneumonia, nocardia, fungi

clinical: indolent symptoms weeks-months

CXR: infiltrates with cavity +/- ring enhancement

diagnosis: transtracheal/bronchoscopic aspirates (sputum contaminated)

treatment: IV AB

35
Q

Lung volumes

A
36
Q

Lymphocytic interstitial pneumonitis

A

incidence: most common form paediatric ILD

pathogenesis: cause unknown ?EBV

2 patterns:

perinatal HIV: 25-40% children by 2-3yrs

  • insidious onset cough, dyspnoea, clubbing
  • LN, HSM, salivary gland enlargement
  • hypergammaglobulinaemia
  • can spontaneously resolve or progress to respiratory failure

others: idiopathic, AI associated

  • tachypnoea, cough, respiratory infections, crepitations
  • LN rare

diagnosis:

  • biopsy
  • CXR: diffuse reticulonodular pattern with hilar adenopathy, ground glass

PFTs: restrictive

treatment: steriods, hydroxychloroquinolone

prognosis: high long term mortality

37
Q

Maternal smoking

A

prenatal: reduced fetal O2

  • placenta (reduced cap volume, spasm)
  • CO exposure
  • nicotine effect lung development
  • spontaneous loss

birth:

  • LBW <2500g, preterm, PPROM, placenta previa/abruption
  • decreased preeclampsia

postnatal:

  • decreased milk supply
  • 1.4x neonatal death, SIDS RR 2-7
  • asthma, OM, colic, short, behavioural issues, metabolic sx
38
Q

Methaemoglobin

A

pathology: iron in Fe3+ form and unable to bind oxygen

normal %: 1-2%

causes of increased MetHb:

  • medications: NO, dapsone, nitrates, benzocaine, sulfonamides
  • disease: GIT infection, sepsis, SS crisis
  • genetic: NADH MetHb reductase def, PKD, G6PD, HbM disease

clinical:

  • oximetry reads 85% regardless of saturations
  • 3-15%: grey/blue discolouration
  • 25-50%: headache, dyspnoea, weakness, confusion
  • 50-70%: arrythmia, altered GCS

treatment:

  • methylene blue: 1st line antidotal agent accelerates the enzymatic reduction of MetHb
  • hyperbaric oxygen
  • RBC exchange transfusions
39
Q

Mixed obstructive/restrictive

A

diagnosis: FEV1 out of proportion to decreasd FEV1/FVC

40
Q

Mycoplasma pneumonia

A

incubation: 3 weeks

incidence: 50% pneumonia in adolescence

clinical: headache, malaise, low grade temp, resp sx, pharyngitis

  • extrapulmonary: haemolysis, rash, CNS involvement (transverse myositis, PN), GI, polyarthritis

associations: common in HIV

diagnosis:

  • serum: haemolysis, neutrophilia, elevated titres (7-9 days)

CXR: peribronchial pneumonia with areas of atelectasis and interstitial infiltration

  • pleural effusion 20%
41
Q

Obstructive disease

A

definition: cause airflow limitation in expiration

diagnosis:

  • increased RV/FRC(gas trapping)
  • decreased PEF
  • _FEV1 _correlates severity
  • FEF 25-75: more accurate but less reliable (use in severe)
42
Q

Obstructive sleep apnoea

A

incidence: 27% children snore and 5% OSA, age 2-8 years

pathophysiology: reduced cross sectional area of upper airway during inspiration

  • increased airway resistance/reduced pharyngeal dilators cause negative pressure and upper airway collapse

risk factors:

  • tonsils: increase in size to age 12, smoking, rhinitis
  • other: obesity, family history, T21

clinical:

  • night: loud disruptive snoring with pauses/choking/arousals, restless sleep
  • day: morning headache, dry mouth, nasal congestion, poor appetitie, FTT, secondary enuresis, behavioural issues

diagnosis: polysomnogram

  • positive if hypopnoea index >1/hour of sleep

treatment: adenotonsillectomy, weight loss, CPAP

43
Q

Parapneumonic effusion/empyema

A

incidence: 5-10% all children with pneumonia

organisms: S.pneumonia, S.aureus, mycoplasma (20%), viral (10%)

pathophysiology: collection of pus in the pleural cavity

  • 3 stages: exudative, fibrinopurulent, organization

clinical:

  • as for pneumonia with dullness to percussion, fever, malaise, chest pain
  • consider in anyone febrile or unwell post IVAB

complications: bronchopleural fistula, pyo-pneumothorax

CXR: white out +/- mediastinal shift

US: to confirm if loculated or simple

diagnosis: fluid (MCS, exudate vs transudate)

treatment:

  • small <5 days: IVAB
  • large/distress/>5 days: thoracocentesis or chest drain
  • persistent: VATS, chest tube
44
Q

Pleural fluid

  • transudate vs exudate-
A

Transudate

cause: increased hydrostatic pressure, decreased colloid/osmotic pressure

appearance: clear

content: SG<1.012, protein <25g/L, cholesterol <45mg/dL

fluid protein:serum protein <0.5

fluid albumin:serum albumin >1.2g/L

fluid LDH: <0.6

Exudate

cause: inflammation

appearance: cloudy

content: SG>1.020, protein >29g/L, cholesterol >45mg/dL

_fluid protein:serum protein >_0.5

_fluid albumin:serum albumin <_1.2g/L

fluid LDH: >0.6

45
Q

Pneumocystis jirovecci pneumonia

A

clinical: insidious onset fever (80-100%), cough, dyspnoea, crepitations, HSM

  • also weight loss, chills, fatigue

CXR: diffuse alveolar infiltrates, pleural effusions

46
Q

Polysomnography

‘Sleep study’

A

apnoea: >90% decrease in airflow lasting >90% duration of 2 normal breaths

  • obstructive: continuous inspiratory effort during apnoea
  • central: no effort with desats >3%, assoc decreased HR

RERA (respiratory effort related arousal):

  • duration of 2 breaths with increasing resp effort, flattening of insp portion of nasal pressure wave/snoring/high CO2 leading to arousal

apnoea hypopnoea index (AHI): no. apnoeas + hypopnoeas per hour

respiratory disturbance index (RDI): no. apnoeas/hypopnoeas/RERAS per hour

obstructive hypoventilation: end tidal CO2 exceeds 50mmHg for >25% of sleep

positive diagnosis: apnoea-hypopnoea index>1 and minimum sats<92%

47
Q

Primary ciliary dyskinesia

A

incidence: 1/10,000, M=F

definition: congenital impairment of mucociliary clearance

pathophysiology: defect in airway cilia causing immotility/aplasia

  • deletion dynein (commonest), absence radial spokes, abscent central tubule
  • defect in nodal cilia controlling normal position of heart/viscera

genetics: AR, heterogenous, defective central cilia, flagella, matrix etc.

clinical: cough/rhinitis/sinusitis +/- nasal polyps/agenesis frontal sinus

  • pulmonary: URTIs, chronic cough, wheeze, obstruction
  • rhinosinusitis: nasal congestion, polyposis
  • otitis: defective ciliary function middle ear causing recurrent OM
  • situs inversus: 50% PCD
  • fertility: males immotile sperm, women<50% change pregnancy

diagnosis: nasal nitric oxide, measure mucociliary clearance, nasal/bronchial brushings, EM (absence dynein arms)

monitoring: PFTs, CXR, HRCT

management: physio, mucolytics, AB, vaccinations, sinus surgery, lung transplant

prognosis: slower decline than CF

48
Q

Pulmonary bronchogenic cysts

A

incidence: most common LRT malformation

pathogenesis: arise from anomalous budding of foregut during development at any part of the tracheobronchial tree

clinical: infants with rapidly enlarging cysts may become symptomatic

  • more commonly present 2nd decade with coughing, wheeze, pneumonia

diagnosis:

  • CXR: round water-density mass
  • CT: marginated cystic mediastinal mass with water attenuation

management: surgical excision

49
Q

Pulmonary eosinophilia

A

pathophysiology: group of diseases with increased eosinophils in lungs/serum

causes:

  • helminth/non-helminth infections
  • drugs: NSAIDs, ampicillin, sulfonamides
  • idiopathic acute/chronic eosinophilic pneumonia
  • Churg-Strauss (medium vasculitis): eosinophilic granulomatosis with polyangitis (sinusitis, asthma)
  • ABPA
  • hypereosinophilic sx

CXR: ground glass opacities

treatment: steroids

50
Q

Pulmonary Hypoplasia

A

pathogenesis: failure of lobe or lung to develop

imaging: mimics lobectomy

associations: spinal abnormalities

51
Q

Pulse oximetry

A

Falsely high: carboxyhb, methb, sick cell

Falsely low: hypoperfusion, anaemia, venous congestion

Left shift (increased binding):

  • fetal Hb, low H+/CO2/temp/2,3 BPG

Right shift (decreased binding):

  • high H+/CO2/temp/2,3 BPG
52
Q

Respiratory function in achondroplasia

A

pathophysiology: abnormal development base of skull forming small foramen magnum that can compress cervicomedullary region causing apnoeas

clinical: apnoea, cyanosis, feeding issues, quadriparesis, death

53
Q

Respiratory function in NMD

A

disorders: muscular dystrophy, congenital/metabolic myopathy, anterior horn cell disorders, PN, NMJ disorders

pathophysiology: decreased muscle strength affects muscles of respiration reducing upper airway patency, cough and lung function

  • leading cause of morbidity/mortality in progressive NMD
  • inadequate ventilation may first manifest during sleep due to upper airway obs/reduced respiratory muscle function in sleep

diagnosis:

  • PFTs: restrictive pattern with decresaed VC/FVC
  • polysomnography: gold standard

treatment: BiPAP, oxygen contraindicated

54
Q

Restrictive disease

A

diagnosis:

  • TLC<80%
  • decreased VC
  • decrease RV in intrinsic, normal RV in chest wall pathology

causes: intrinsic lung disease, chest wall pathology, NMD

55
Q

Spirometry

A

FEV1: most reproducible

FEV25-75 (MMEFR): most accurate for small airway obstruction but variability

PEFR: monitor disease progression

Poor effort: usually problem with sustaining adequate exp

Variation: require 3 attempts within 5% of each other

56
Q

Spirometry for asthma

A

FEV1: gold standard for diagnosis and monitoring

FEV1/FVC= <80%

post bronchodilator: FEV1 increase 12%

bronchial challenge (histamine, mannitol, exercise)

withhold:

  • beta agonists: short 8hr, medium 24hr, long 48hr
  • theohylline 12-48hr
  • leukotriene 24hr
  • antihistamine 24-62hr
  • tea/coffee/cola 24hr

aim: drop FEV1 20% (normal all subjects) but at smaller doses for asthmatics ie. 0.8 vs 20mg/ml

57
Q

Staphylococcal pneumonia

A

clinical: acute and rapid course

CXR:

  • early illness: lobar changes with pleural effusions
  • late illness: wides opacifications, large pleural effusions, displaced intrathoracic structures, abscesses, airleaks (highly specific)
58
Q

Stridor

A

1) laryngomalacia
2) subglottic stenosis
3) vocal cord palsy

59
Q

Subglottic stenosis

A

incidence: 2nd most common cause neonatal stridor

pathophysiology:

  • primary: congenital
  • secondary: intubation, silent GOR, diptheria, burns

clinical: biphasic/inspiratory stridor

investigation: laryngoscopy

management: improves with age but surgery may be required

60
Q

Transfer factor

A

TLCO or DLCO (transfer or diffusing capacity)

  • the extent to which oxygen passes from alveoli into blood

Transfer resistance=1/TLCO

Transfer coefficient (KCO)=TLCO/VA (VA=alveolar vol)

KCO increased: restrictive defects eg. NMD, obesity

KCO decreased: parenchymal/pulmonary disease eg. ILD

61
Q

Vocal cord palsy

A

incidence: 3rd most common cause neonatal stridor

pathophysiology

  • unilateral: paralysed VC abducted
  • bilateral: paralysed in adduction causing obstruction

cause

  • iatrogenic (cardiac/thyroid surg), idiopathic (viral, AI), neurologic/central (Arnold-Chiari, tumour, hydroceph), injury/compression recurrent laryngeal nerve, trauma (birth)

clinical

  • unilateral: absent/weak cry, stridor, aspiration, coughing, choking
  • bilateral: biphasic stridor, normal cry, weak voice

diagnosis: nasolaryngoscopy

prognosis: resolved within 6-12 months

treatment

unilateral: speech tx, surgery if aspiration of poor voice quality

bilateral: surgery to open/lateralise VC for airway, tracheo in 50%

62
Q

Physiology of sleep

A

tidal volume: decrease by 1/2

upper airway resistance: increase by 2

63
Q

Stages of Sleep

A

N1: transition to light sleep (easily roused)

N2: light sleep (k complexes and spindles)

N3: deep sleep or slow wave sleep (hard to rouse, regular breathing)

REM: decreased tone, rapid eye movement, partial paralysis, vivid dreams, irregular breathing

64
Q

Neonatal sleep

A

2 stages

  1. deep sleep
  2. REM sleep
65
Q

Prevalence OSA/snoring

A

OSA: 1-3%

  • assoc: snoring >50% night, mouth breathing, struggling to breath, parental concern
  • outcome: decrements memory/attention

snoring: 10-13%

66
Q

Nitric Oxide Tests

A

HIGH exhaled NO: eosinophilic inflammation

  • eg. asthma FeNO>33ppb

LOW nasal nitric oxide:

  • PCD/CF